Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
allergan
3
×
biotech
clinical trials
life sciences
national blog main
boston blog main
boston top stories
eli lilly
europe blog main
fda
national top stories
alkermes
alzheimer's disease
amgen
biohaven
boston
buprenorphine
cariprazine
cgpr
crispr
cynthia collins
deals
editas medicine
europe
europe top stories
felipe jain
gene editing
jess fiedorowicz
jessica jeffrey
karim calis
leber congenital amaurosis type 10
lumateperone
m health fairview
marc goodman
massachusetts general hospital
merck
michelle robertson
migraine
national
What
treatment
3
×
fda
medicines
abbvie
adults
alkermes
allergan
alliance
antipsychotic
approved
benefits
biotech
caveats
class
commonly
designed
drug
editas
editing
effect
exits
experimental
favor
gain
gene
genetic
medicine
migraine
monday
new
nod
offer
pact
panel
partnership
pill
prescribed
pruning
psyche
research
Language
unset
Current search:
allergan
×
treatment
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
